Research programme: VEGFR2 inhibitors - ChemDiv
Latest Information Update: 15 Apr 2009
At a glance
- Originator ChemDiv
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 15 Apr 2009 No development reported - Preclinical for Cancer in USA (unspecified route)
- 06 Dec 2005 Preclinical trials in Cancer in USA (unspecified route)